P2, N=10, Terminated, Mario Negri Institute for Pharmacological Research | Trial completion date: Jun 2026 --> Jan 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jan 2025; Low enrolment rate

3 days ago

Trial completion date • Trial termination • Trial primary completion date

PD-L1 (Programmed death ligand 1)

cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • vinorelbine tartrate

INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)

P2, N=180, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

6 days ago

Enrollment open

Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)

HYPERBOLIC: Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial (clinicaltrials.gov)

P2, N=74, Not yet recruiting, Università Vita-Salute San Raffaele

9 days ago

New P2 trial • IO biomarker

PD-L1 (Programmed death ligand 1)

cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)

Comparative effectiveness and safety of systemic therapies for treatment-naïve, PD-L1 expression <1% advanced NSCLC: a systematic review and network meta-analysis. (PubMed, Transl Lung Cancer Res)

In terms of OS, pembrolizumab + chemotherapy + canakinumab (Pembro-chemo-canakinumab) (SUCRA =0.90) showed great potential in improving outcomes, although its long-term efficacy still needed to be validated...For squamous patients, nivolumab + ipilimumab ± chemotherapy (Nivo-ipi-chemo) led in OS, while serplulimab + chemotherapy in PFS. First-line personalized treatment for PD-L1 <1%, advanced NSCLC should be histology-based, balancing efficacy and toxicity. Pembro-chemo and nivolumab + chemotherapy + bevacizumab combinations are recommended as the optimal first-line options for non-squamous patients, and Nivo-ipi-chemo for squamous patients.

9 days ago

Retrospective data • Journal • HEOR • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • Hetronifly (serplulimab) • Ilaris (canakinumab)

10d

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov)

P2, N=104, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

10 days ago

New P2 trial

carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)

16d

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) (clinicaltrials.gov)

P3, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

16 days ago

Enrollment closed

Keytruda (pembrolizumab)

23d

NIRVANA-LUNG: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)

P3, N=327, Recruiting, UNICANCER | Active, not recruiting --> Recruiting | Trial completion date: Jul 2027 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026

23 days ago

Enrollment open • Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK positive • ALK translocation

Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed

23d

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (clinicaltrials.gov)

P2, N=102, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

23 days ago

Trial completion

PD-L1 (Programmed death ligand 1)

Keytruda (pembrolizumab) • MK-0482 • MK-4830

23d

Radiation Recall Pneumonitis with Pneumocystis jirovecii Superinfection and Treatment Induced Hyponatremia in a Patient with Non-Small-Cell Lung Cancer. (PubMed, Diseases)

We report a unique case of a 65-year-old man with squamous-cell NSCLC and high PD-L1 expression (80%), who developed a rare complication: radiation recall pneumonitis (RRP), with superimposed Pneumocystis jirovecii pneumonia and severe symptomatic hyponatremia induced by trimethoprim/sulfamethoxazole (TMP-SMX). The coexistence of these three complications-radiotherapy- and immunotherapy-associated lung injury, opportunistic infection, and electrolyte imbalance-represents an exceptional clinical scenario not previously described in the literature. This report highlights the importance of differential diagnosis, early recognition of complications, and close monitoring of electrolytes in NSCLC patients undergoing complex treatment regimens.

23 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1)

PD-L1 expression • PD-L1 overexpression

Keytruda (pembrolizumab)

25d

LUCENCE: A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus (clinicaltrials.gov)

P=N/A, N=212, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=350 --> 212

25 days ago

Trial completion • Enrollment change • Real-world evidence

Opdivo (nivolumab)